SCHEMBL13764757

SCHEMBL13764757

CC1=C(c2cn3cnc(C(=O)c4cccnc4)c3s2)[C@H](C)[C@@H]2[C@@H](C(C)C)C(=O)N12

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13764793 0.94 CCNA2 (0.30) CCNA2CDK2
SCHEMBL13764791 0.88
SCHEMBL3871785 0.85 ESR1 (0.35) CCNA2CDK2
SCHEMBL13764758 0.82
SCHEMBL13764785 0.79
SCHEMBL5233425 0.78 ESR1 (0.32)
SCHEMBL5232640 0.76 ESR1 (0.34)
SCHEMBL5235538 0.76 ESR1 (0.37)
SCHEMBL4155818 0.75 MAPT (0.33)
SCHEMBL5231629 0.75 ESR1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563901-B2 Intermediates of 2-substituted carbapenem derivatives and process for production thereof MEIJI SEIKA KAISHA, LTD. (JP) 2009-07-21 US disclosed
US-7524951-B2 Intermediates of 2-substituted carbapenem derivatives and process for production thereof MEIJI SEIKA KAISHA, LTD. (JP) 2009-04-28 US disclosed
US-20090082571-A1 Intermediates of 2-substituted carbapenem derivatives and process for production thereof SASAKI TOSHIRO 2009-03-26 US disclosed
US-20080167475-A1 Intermediates of 2-substituted carbapenem derivatives and process for production thereof SASAKI TOSHIRO 2008-07-10 US disclosed
US-20080076917-A1 Intermediates of 2-Substituted Carbapenem Derivatives and Process for Production Thereof MEIJI SEIKA KAISHA, LTD. (JP) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167475-A1 Intermediates of 2-substituted carbapenem derivatives and process for production thereof MGAM, G6PD, COASY CCNA2 3080/4885CDK2 1729/4885
US-20080076917-A1 Intermediates of 2-Substituted Carbapenem Derivatives and Process for Production Thereof MGAM, G6PD, COASY CCNA2 3080/4885CDK2 1729/4885
US-20090082571-A1 Intermediates of 2-substituted carbapenem derivatives and process for production thereof MGAM, G6PD, COASY CCNA2 3080/4885CDK2 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.